Pune, Oct. 06, 2020 (GLOBE NEWSWIRE) -- The global adalimumab biosimilar market is poised to experience a steady growth period owing to the rising incidence of arthritis. According to the World Health Organization (WHO), rheumatoid arthritis affects 0.3 to 1% of people in the developed countries and about 50% of them are forced to quit their jobs after the onset of the disease. On the other hand, osteoarthritis hits 9.6% of men and 18% of women over the age of 60 globally. The Arthritis Foundation predicts that 78 million Americans will be suffering from arthritis by 2040, with 54 million already affected by it. The global adalimumab biosimilar market stands to gain from this growing prevalence as adalimumab is an effective treatment option for various kinds of arthritis.
A monoclonal antibody, adalimumab is designed to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, and many more. It achieves this by inhibiting the soluble inflammatory cykotine, Tumor Necrosis Factor (TNF). The product originated from AbbVie’s Humira, which got cleared by the US FDA in 2002 and the European Medicines Agency in 2003.
Key Industry Developments:
- In October 2018, Samsung Bioepis launched IMRALDITM a biosimilar to adalimumab with joint venture between Samsung BioLogics and Biogen.
- In November 2018, Food and Drug Administration approved the Hyrimoz adalimumab biosimilar developed by Novartis AG.
- In October 2018, Amgen Inc., launched AMGEVITA a biosimilar of adalimumab.
- In August, 2017, Boehringer Ingelheim International GmbH received approval for the Cyltezo, a biosimilar of adalimumab.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/adalimumab-biosimilar-market-101222
Proliferation of Skin Disorders to Fuel the Market
According to the WHO, skin afflictions are the most commonly affecting disorders harming human health. The WHO estimates that around 900 million people in the world suffer from skin diseases at any given point of time. Many of these skin disorders lead to lifelong disfigurement, stigma, and disability and treating them effectively has become major concern for health organizations the world over.
In this backdrop, adalimumab biosimilar has emerged as a viable treatment option for chronic skin diseases such as eczema. This factor can considerably swell the global adalimumab biosimilar market size in the forecast period. A biosimilar is a biological product having characteristics similar to those of its biologic reference product and targets specific areas in the immune system to treat the disease.
Owing to its multiple advantages, especially in treating psoriasis, adalimumab biosimilar is emerging as a preferred option to tackle skin disorders.
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/adalimumab-biosimilar-market-100594
Rising Prevalence of Autoimmune Diseases to Drive the Market in North America
The American Autoimmune Related Diseases Association estimates that around 50 million Americans suffer from some kind of autoimmune disease. Moreover, the healthcare costs of treating these diseases is close to USD 100 billion annually. This, along with an increasing aged population, is expected to give North America the largest percentage of the global adalimumab biosimilar market share during the forecast period.
Rising geriatric population and increasing public and private investment in pharmaceuticals are factors that will propel the market in Europe. The market in Asia-Pacific is expected to be driven by the growing investments in medicine research.
Regulatory Approvals to Spur Competition; Boehringer’s Cyltezo Gets FDA Approval
Cyltezo, a biosimilar of adalimumab developed by Boehringer Ingelheim International, got the green light from the US FDA in August 2017. Such regulatory clearances to novel products are expected to encourage other players to make greater investments in research and development and come out with innovative products.
Some players in the global adalimumab biosimilar market are already engaged in developing new products and expanding their product portfolios. For instance, Glenmark Pharmaceuticals launched ADALY, its adalimumab biosimilar drug, in Mumbai in January 2018 through a licensing agreement with Cadila Healthcare.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/adalimumab-biosimilar-market-101222
Fortune Business Insights covers some of the important competitors in the global adalimumab biosimilar market:
- Zydus Cadila
- Alfred E. Tiefenbacher
- Torrent Pharmaceuticals Ltd
- Cipla Inc.
- Glenmark Pharmaceuticals Ltd
- Emcure Pharmaceuticals Ltd
- Boehringer Ingelheim International GmbH
- Reliance Life Sciences
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/adalimumab-biosimilar-market-101222
Adalimumab Biosimilar Market Segmentations:
By Product
• Exemptia
• Adalirel
• Cipleumab
• Others
By Distribution channel
• Hospitals pharmacies
• Retail pharmacies
• Others
By Geography
• North America (USA and Canada)
• Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
• Latin America (Brazil, Mexico and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Have a Look at Related Reports:
Autism Spectrum Disorder Therapeutics Market Share and Global Trend By Type (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, Others), By Treatment Type (Communication & Behavioral Therapies, Drug Therapies) and Geography Forecast till 2026
Revenue Cycle Management Market Share and Global Trend By Structure (In-house Outsource) By Function (Claims & Denial Management, Medical Coding & Billing, Clinical Documentation Improvement (CDI), Insurance, Others) By Type (Software, Services) and Geography Forecast till 2026
ePharmacy Market Share and Global Trend By Product (Over-the-Counter Products, Prescription Medicine) and Geography forecast till 2026
Antipsychotic Drugs Market Share and Industry Analysis, By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Others), By Therapeutic Class (First Generation, Second Generation, Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019 – 2026
Europe Compression Bandages Market Share & Industry Analysis, By Product (Short Stretch Bandages, Long Stretch Bandages, Multilayer Compression Bandages), By Material (Polyster, Latex, Cotton, Others), By Application (Wound Management, Deep Vein Thrombosis, Lymphedema, Others), By End-user (Hospitals & Ambulatory Surgical Centers, Clinics, Nursing Care Centers & Skilled Nursing Facilities, Home Care, Others) and Regional Forecast, 2019 - 2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs